NCT04606381: A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies

NCT04606381
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have either progressed after prior standard of care therapy for metastatic disease
Exclusions: Patients with unstable, symptomatic, uncontrolled brain metastases- see trial for details; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT04606381

Comments are closed.

Up ↑